Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04896320
Title Tucatinib With Chemotherapy and Trastuzumab in Advanced Her-2-neu Overexpressing, Previously Treated Breast Cancer. (2019-101826)
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Providence Health & Services

Her2-receptor positive breast cancer


Trastuzumab + Tucatinib + Vinorelbine

Capecitabine + Trastuzumab + Tucatinib

Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.